Molecular Templates, Inc.: debt financing — MTEM restructures $37.8M K2HV debt with $27.5M cash, CVR, and warrants; cuts 44% workforce

Molecular Templates, Inc.

Paid $27.5M to settle $37.8M K2HV loan; remaining ~$10M converted to contingent value rights (CVR) with multipliers up to 2.5x.
K2HV received warrant to buy 5,103,343 shares at $0.3919, plus right to convert $3M of CVR into 6,124,011 shares.
Workforce reduced by ~44% (from 105 to ~46 employees) to extend cash runway while pursuing strategic alternatives.
Company exploring strategic alternatives with Stifel; no timeline set and no assurance of a completed transaction.

item 1.01 item 1.02 item 2.03 item 2.05 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Molecular Templates, Inc. incurred debt of Remaining Value which is initially $10,303,646 with K2 HealthVentures LLC.

Principal: Remaining Value which is initially $10,303,646
Counterparty: K2 HealthVentures LLC
Event: incurrence

Exact text from the filing

The payment due upon any Contingent Payment Event or an Acceleration Event is capped at an amount (the “Remaining Value”) which is initially $10,303,646

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001193125-23-169552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.